Systemic DKK1 neutralization enhances human adipose-derived stem cell mediated bone repair

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Orthopedic Research

Background:

• Adipose-derived stem cells (ASCs) show potential for bone repair, but efficacy is inconsistent.
• Wnt signaling antagonists, like Dickkopf-1 (DKK1), can inhibit ASC function.
• DKK1 expression varies in human ASCs, potentially limiting their bone-healing capacity.

Purpose of the Study:

• To investigate the therapeutic potential of blocking DKK1 to enhance ASC-mediated bone regeneration.
• To evaluate the effect of anti-DKK1 antibodies on ASC osteogenic differentiation and in vivo bone repair.

Main Methods:

• Human ASCs were treated with anti-DKK1 antibodies in vitro.
• ASCs were engrafted into mouse femoral bone defects and treated systemically with anti-DKK1 or control.
• Bone repair, ASC engraftment, survival, and vascularization were assessed.

Main Results:

• Anti-DKK1 treatment increased in vitro osteogenic differentiation of ASCs via Wnt signaling.
• Systemic anti-DKK1 enhanced ASC engraftment, survival, and vascular ingrowth in vivo.
• Significant improvements in bone repair were observed in the anti-DKK1 treated group.

Conclusions:

• Neutralizing DKK1 with antibodies is a viable strategy to augment ASC-driven bone regeneration.
• This method holds promise for improving outcomes in challenging bone healing scenarios, such as osteoporotic fractures.